首页> 外文期刊>Pituitary >Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence
【24h】

Long-term cardiometabolic outcome in patients with pituitary adenoma diagnosed in chilhood and adolescence

机译:脑脑垂体腺瘤患者的长期心肌蛋白结果

获取原文
获取原文并翻译 | 示例
       

摘要

Purpose Pituitary adenomas (PAs) rarely occur in childhood and adolescence. Management of PAs in this critical age can be particularly challenging considering the auxological sequelae and potential long-term cardiometabolic consequences. We aimed to describe the clinical characteristics of patients with PA aged < 18years at diagnosis and during long-term follow-up, focusing on the prevalence of cardio-metabolic comorbidities and the impact of different therapeutic strategies. Methods Clinical data at diagnosis and at last follow-up visit (mean 10.3 +/- 9.2 years) of 101 patients aged < 18 years with PA, referred to our University Hospital from 1990 to 2017, were retrospectively evaluated. Results At diagnosis, 11.9% of patients presented with pituitary hormone deficiencies, whose number was positively correlated with pituitary tumor diameter (p < 0.001). At diagnosis, 26.7% of patients were overweight and 15.8% were obese. In patients with hypercortisolism or GH excess the prevalence of obesity was more than 2-fold greater than in general population. No correlation was found between pituitary tumor size and BMI. At baseline, the greater the number of pituitary hormone deficits, the higher BMI (p = 0.039). In prolactinoma patients still on medical therapy at last visit, BMI was higher than at baseline. Conclusion We found an increased prevalence of overweight/obesity only in pediatric and adolescent patients with GH- or ACTH-secreting PA. Regarding cardio-metabolic comorbidities other than obesity/overweight, we have not found anything worth of mention. The remission of hypercortisolism positively impacted on BMI, while medical therapy in patients with prolactinoma seemed unable to avoid weight gain, suggesting a careful metabolic management of these patients.
机译:目的垂体腺瘤很少发生在儿童和青少年时期。考虑到营养不良后遗症和潜在的长期心脏代谢后果,在这个关键年龄段对PAs的管理可能特别具有挑战性。我们的目的是描述年龄<18岁的PA患者在诊断和长期随访期间的临床特征,重点关注心脏代谢性共病的患病率和不同治疗策略的影响。方法回顾性分析1990年至2017年我校医院收治的101例年龄<18岁的PA患者的诊断和最后一次随访(平均10.3+/-9.2年)的临床资料。结果诊断时,11.9%的患者出现垂体激素缺乏,其数量与垂体瘤直径呈正相关(p<0.001)。诊断时,26.7%的患者超重,15.8%的患者肥胖。在皮质醇过高或生长激素过量的患者中,肥胖的患病率是普通人群的2倍多。垂体瘤大小与BMI之间无相关性。在基线检查时,垂体激素缺陷的数量越多,BMI越高(p=0.039)。在最后一次就诊时仍在接受药物治疗的泌乳素瘤患者中,BMI高于基线水平。结论:我们发现,仅在分泌GH或ACTH的PA的儿童和青少年患者中超重/肥胖的患病率增加。关于肥胖/超重以外的心脏代谢共病,我们没有发现任何值得一提的情况。高皮质醇症的缓解对BMI有积极影响,而对泌乳素瘤患者进行药物治疗似乎无法避免体重增加,这表明对这些患者进行谨慎的代谢管理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号